The Prognostic Role of Optimal Cytoreduction in Advanced, Bowel Infiltrating Ovarian Cancer

REFERENCES

• Abe A, Furumoto H, Irahara M, et al. The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer. J Obstet Gynaecol Res. 2010 Oct;36(5):1023–1030.
   Google Scholar
• Aletti GD, Dowdy S, Podratz KC, et al. Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. Am J Obstet Gynecol. 2006 Dec;195(6):1862–1868.
   PubMed Web of Science ®Google Scholar
• Aletti GD, Dowdy SC, Podratz KC, et al. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol. 2007 Apr;105(1): 84–89.
   Google Scholar
• Balbi G, Manganaro MA, Monteverde A, et al. Ovarian cancer: lymphnode metastases. Eur J Gynecol Oncol. 2009;30(3):289–291.
   Google Scholar
• du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer. March 15, 2009:1234–1244.
   Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002 Mar 1;20(5):1248–1259.
   PubMed Web of Science ®Google Scholar
• Carnino F, Fuda G, Ciccone G, et al. Significance of lymph node sampling in epithelial carcinoma of the ovary. Gynecol Oncol. 1997 Jun;65(3):467–472.
   Google Scholar
• Chan JK, Urban R, Hu JM, et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer. 2007 Jun 18;96(12):1817–1822. Epub 2007 May 22.
   PubMed Web of Science ®Google Scholar
• Crawford SC, Vasey PA, Paul J, et al. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol. 2005 Dec 1;23(34):8802–8811. Erratum in: J Clin Oncol. 2006 Mar 1;24(7):1224.
   Google Scholar
• Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998 May;69(2):103–108.
   PubMed Web of Science ®Google Scholar
• Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007 Nov–Dec;17(6):1238–1244. Epub 2007 Apr 12.
   PubMed Web of Science ®Google Scholar
• Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009 May;16(5):1324–1330. doi:10.1245/s10434-009-0357-0. Epub 2009 Feb 19.
   Google Scholar
• Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006 Dec;13(12):1702–1710.
   PubMed Web of Science ®Google Scholar
• Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994 Apr;170(4):974–979.
   PubMed Web of Science ®Google Scholar
• Kaku T, Ogawa S, Kawano Y, et al. Histological classification of ovarian cancer. Med Electron Microsc. 36(1):9–17, 2003.
   PubMedGoogle Scholar
• Mayr D, Diebold J. Grading of ovarian carcinomas. Int J Gynecol Pathol. 2000 Oct;19(4):348–353.
   Google Scholar
• Onda T, Yoshikawa H, Yasugi T, et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to stage I/II patients and superior survival to other stage III patients. Cancer. 1998 Oct 15;83(8):1555–1560.
   Google Scholar
• Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005 Apr 20;97(8):560–566.
   PubMedGoogle Scholar
• di Re F, Baiocchi G, Fontanelli R, et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. Gynecol Oncol. 1996 Sep; 62(3):360–365.
   Google Scholar
• Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol. 2001 Feb;127(2):73–79. Review.
   Google Scholar
• Polterauer S, Vergote I, Concin N, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA–IV: analysis of the OVCAD data. Int J Gynecol Cancer. 2012 Mar;22(3):380–385.
   PubMed Web of Science ®Google Scholar
• Scarabelli C, Gallo A, Visentin MC, et al. Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease. Int J Gynecol Cancer. 1997 Jan;7(1):18–26.
   Google Scholar
• Winter WE III, Maxwell GL, Tian C, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2008 Jan 1;26(1): 83–89.
   Google Scholar
• Takeshima N, Hirai Y, Umayahara K, et al. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. Gynecol Oncol. 2005 Nov;99(2):427–431. Epub 2005 Aug 19.
   PubMed Web of Science ®Google Scholar
• Whittemore, AS. Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol. 1994 Dec;55(3 Pt 2):S15–S19.
   Google Scholar
• Wimberger P, Lehmann N, Kimmig R, et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2007 Jul; 106(1): 69–74.
   Google Scholar
• Kim HS, Ju W, Jee BC, et al. Systematic lymphadenectomy for survival in epithelial ovarian cancer. Int J Gynecol Cancer. 2010 May;20(4):520–528. doi:10.1111/IGC.0b013e3181d6de1d.
   Google Scholar
• Jaeger W, Ackermann S, Kessler H, et al. The effect of bowel resection on survival in advanced epithelial ovarian cancer. Gynecol Oncol. 2001;83:286–291.
   PubMedGoogle Scholar
• Kalogera E, Dowdy SC, Mariani A, et al. Multiple large bowel resections: potential risk factor for anastomotic leak. Gynecol Oncol. 2013 Jul;130(1):213–218. doi:10.1016/j.ygyno.2013.04.002. Epub 2013 Apr 8.
   Google Scholar
• Barlin JN, Long KC, Tanner EJ, et al. Optimal (≤.1 cm) but visible residual disease: is extensive debulking warranted? Gynecol Oncol. 2013 Aug;130(2):284–288. doi:10.1016/j.ygyno.2013.05.006. Epub 2013 May 11.
   Google Scholar
• Scarabelli C, Gallo A, Franceschi S, et al. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer 2000;88:389–97.
   Google Scholar
• Spirtos NM, Eisenkop SM, Schlaerth JB, et al. Second-look laparotomy after modified posterior exenteration: patterns of persistence and recurrence in patients with stage III and stage IV ovarian cancer. Am J Obstet Gynecol. 2000;182:1321.7.
   Google Scholar
• Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival? Gynecol Oncol. 2001;82:435.41.
   Google Scholar
• Peiretti M, Bristow RE, Zapardiel I, et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol. 2012 Aug;126(2):220–223. doi:10.1016/j.ygyno.2012.04.030. Epub 2012 Apr 30.
   PubMed Web of Science ®Google Scholar
• Chekerov R, Braicu I, Castillo-Tong DC, et al. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD. Int J Gynecol Cancer. 2013 Feb;23(2):268–275. doi:10.1097/IGC.0b013e31827de6b9.
   Google Scholar